Purchase Order 75N93018P00890

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for custom peptide synthesis on September 13, 2018, with a ceiling value of $17,503.39.</p> <p>Work is performed in Piscataway, New Jersey. The order is firm fixed price with an ultimate completion date of October 31, 2018. No set-aside category applies.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for antibody gene synthesis and production, valued at $16,974.27, on August 26, 2020. The order was firm fixed price with an ultimate completion date of February 6, 2021. Work was performed at Genscript's facility in Piscataway, New Jersey.</p>

The Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $11,453 purchase order to Genscript USA Inc. to provide custom peptide synthesis services in support of H1/HA programs. The firm fixed price contract runs from September 18, 2023 through December 29, 2023 and will be performed in Piscataway, New Jersey. Genscript will synthesize peptides to advance NIH's research on influenza viruses under the contract....

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $11,179.50 on November 18, 2019, for customized gene production, gene synthesis, and cloning services.</p> <p>Place of performance is Piscataway, New Jersey. The order carries a firm fixed price and ultimate completion date of December 6, 2019.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. valued at $30,200.12 on September 11, 2017. Performance is at Genscript's facility in Piscataway, New Jersey. The order was firm fixed price with no small business set-aside. Ultimate completion was September 18, 2017.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $15,028.93 on September 10, 2015, for mutagenesis, gene synthesis, custom plasmid preparation, and reagents. Work is performed in Piscataway, New Jersey. The order carries a firm fixed price and no set-aside designation. Ultimate completion is September 13, 2016.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. valued at $1,147,346.00 on September 26, 2019, for customized biologicals under firm fixed pricing. Performance is located in Piscataway, New Jersey. The order has no small business set-aside and carried an ultimate completion date of September 25, 2020. The originating pre-solicitation was posted September 3, 2019, with a due date of September 6, 2019.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for peptide sequencing services on September 5, 2022, with a ceiling value of $23,890.75. No set-aside was used. Work is performed in Piscataway, New Jersey. The order is firm fixed price for FY26 UDO Initiative peptide sequencing services, with an ultimate completion date of October 5, 2022.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $17,209.00 on September 18, 2023, for custom gene synthesis and expression services. Performance occurs in Bethesda, Maryland. The order is firm fixed price with no small business set-aside. The ultimate completion date is December 31, 2023.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for sequencing and gene synthesis services for 100 samples on March 17, 2022, with a ceiling value of $15,389.60. Work is performed in Piscataway, New Jersey. The order is firm fixed price with no set-aside designation and an ultimate completion date of March 16, 2023.</p>